首页> 外文期刊>Neurology Research International >Practice Variations in the Use of Novel Oral Anticoagulants for Nonvalvular Atrial Fibrillation-Related Stroke among Stroke Neurologists in Saudi Arabia
【24h】

Practice Variations in the Use of Novel Oral Anticoagulants for Nonvalvular Atrial Fibrillation-Related Stroke among Stroke Neurologists in Saudi Arabia

机译:在沙特阿拉伯中风神经学家中卒中神经学家非衰高性抗凝血剂使用新口腔抗凝血剂的练习变化

获取原文
       

摘要

Clinical trials have demonstrated that novel oral anticoagulants (NOACs) are noninferior to warfarin in preventing nonvalvular atrial fibrillation- (nvAF-) related stroke and systemic embolism. However, in these trials, NOACs initiation was delayed for a variable period after stroke. Herein, we aimed to investigate the variability in early initiation of NOACs after nvAF-related stroke among stroke neurologists in Saudi Arabia. A standardized questionnaire was distributed electronically to all the stroke neurologists and fellows in Saudi Arabia. The questionnaire primarily focused on the timing of NOACs initiation after an nvAF-related stroke, according to stroke size (small, medium, and large) and location (anterior or posterior circulation). Thirty-six (85.7%) of the 42 stroke neurologists, who were contacted, participated in the survey. All participants would initiate NOACs in the first 3?days after a TIA; most of them initiate NOACs within 7?days after a small stroke, 4–14?days after a medium stroke, and ≥12?days after a large stroke, regardless of stroke location. Presence of a symptomatic intracranial hemorrhage further delayed initiation of NOACs. Additionally, 77.8% of the participants would bridge with antiplatelets before initiation of NOACs, and 55.6% would use a single antiplatelet agent. In conclusion, the practice of stroke neurologists is consistent with and supports the available evidence from observational studies on the time of initiation of NOACs. Our findings provide a guide for clinicians who manage nvAF-related stroke until more robust evidence from randomized controlled trials is available.
机译:临床试验表明,新颖的口腔抗凝血剂(NOACS)是非法于WATFARIN预防非衰弱性颤动 - (NVAF-)相关的中风和全身栓塞。然而,在这些试验中,脱汞后延迟卒中后的可变时期。在此,我们旨在探讨沙特阿拉伯中风神经学家中Nvaf相关中风早期开始的变异性。标准化的问卷是以电子方式分发给沙特阿拉伯的所有中风神经根学家和研究员。根据中风尺寸(小,中等,大的)和位置(前后或后循环),调查问卷主要关注NVAF相关中风后的Noacs引发的时间。联系的42名中风神经学家的32人(85.7%)参加了调查。所有参与者都会在TIA后的前3天在前3天开始NOAC;其中大多数在7-14天后在7-14天后发起巨头,中风后的一天,≥12?大冲程后的一天,无论中风位置如何。存在症状的颅内出血进一步延迟了巨乳的开始。此外,77.8%的参与者将在巨珠开始之前桥接抗血浆,55.6%将使用单一的抗血小板剂。总之,卒中神经根学家的做法与在诺克斯启动时的观察性研究中的可用证据一致。我们的调查结果为管理NVAF相关中风的临床医生提供了指南,直到可随机对照试验的更强大的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号